Jefferies has increased its price target for Novo Nordisk shares to DKK 285, up from the previous DKK 270 level.
The adjustment reflects the investment bank's positive outlook on the company's near-term prospects and market position.
6% upside from the prior valuation, signaling that analysts see further room for appreciation in the stock.
The revised target represents a roughly 5.6% upside from the prior valuation, signaling that analysts see further room for appreciation in the stock.
This move adds to the bullish consensus surrounding one of Europe's most valuable pharmaceutical companies.
Novo Nordisk continues to benefit from strong demand for its diabetes and weight-loss treatments, which have driven consistent revenue growth and expanded market share globally.
The broker's action underscores the enduring investor interest in the firm's pipeline and commercial execution.